Proposed Capital Reduction, Distribution in Specie and notice of General Meeting
Open Orphan PLC (ORPH.L) Potential demerger of certain non-core assets
Open Orphan PLC (ORPH.L) Launch of Disease in Motion platform
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces
Open Orphan PLC (ORPH.L) £7.5m Human Challenge Study Contract
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials.
Open Orphan PLC (ORPH.L) COVID-19 Human Challenge Programme update
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces
Open Orphan PLC (ORPH.L) Journal for Clinical Studies article publication
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that an article
Open Orphan PLC (ORPH.L) New contract win with Oxford BioTherapeutics
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces its subsidiary Venn
Open Orphan PLC (ORPH.L) Ethics approval – COVID-19 Human Challenge Study
Call for volunteers to enrol in studies that will play a key part in developing effective vaccines and treatments for COVID-19
Open Orphan PLC (ORPH.L) New challenge study quarantine clinic
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organization (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that
Open Orphan PLC (ORPH.L) Contract extension with Carna Biosciences
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces
Open Orphan PLC (ORPH.L) Article published in Drug Discovery Today
Article Published in Drug Discovery Today
Open Orphan PLC (ORPH.L) Expansion of volunteer recruitment centres
Expansion of volunteer recruitment centres for human challenge trials Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and the world leader in vaccine
